Merck Will Share Formula for its Covid Pill With Poor Countries
The New York Times
The company announced a licensing deal that will allow the drug, molnupiravir, to be made and sold cheaply in 105 developing nations.
Merck has granted a royalty-free license for its promising Covid-19 pill to a United Nations-backed nonprofit in a deal that would allow the drug to be manufactured and sold cheaply in the poorest nations, where vaccines for the coronavirus are in devastatingly short supply.
The agreement with the Medicines Patent Pool, an organization that works to make medical treatment and technologies globally accessible, will allow companies in 105 countries, mostly in Africa and Asia, to sublicense the formulation for the antiviral pill, called molnupiravir, and begin making it.
Merck reported this month that the drug halved the rate of hospitalizations and deaths in high-risk Covid patients in a large clinical trial. Affluent nations, including the United States, have rushed to negotiate deals to buy the drug, tying up large portions of the supply even before it has been approved by regulators and raising concerns that poor countries would be shut out of access to the medicine, much as they have been for vaccines.
The Chinese social media app, popular in the United States a week after being flooded by TikTok users, has added language translation features.
TikTok’s cultural footprint in America is huge. Why is its disappearance being met with a shrug?
The positions of Robert F. Kennedy Jr. on vaccines and drug companies are well known. His approach to addiction has been far less scrutinized.
Robert F. Kennedy Jr. petitioned the F.D.A. to revoke authorization of the shots at a time when they were in high demand and considered life-saving.
While TikTok remains hugely popular in Brazil, Indonesia and other markets, its 170 million users in the United States are its most valuable.
With Trump back in town, owners are wondering how the dining scene will shape up.
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
A new study reveals the surprising ways rattlesnakes have evolved to collect water in the desert.
Ahead of a potential ban of the app, The Times spoke to 11 prominent food content creators about what is at stake.
While Elon Musk’s spaceflight company repeated a spectacular catch of its powerful booster stage, the upper stage experienced a catastrophic malfunction.
At a small but growing subset of American breweries, a wave of obscure, foam-heavy Czech beers is swelling.
Although long considered a disease of aging, certain cancers are turning up more often in younger women, according to a new report.
The rocket successfully lifted off after the company’s first launch attempt was scrubbed. The flight is a crucial test of the company’s ability to compete with Elon Musk’s SpaceX.
A 28-year-old woman with a busy social life spends hours on end talking to her A.I. boyfriend for advice and consolation. And yes, they do have sex.
New York may be losing its identity as the city that doesn’t sleep, but the motley guests at Kellogg’s Diner show the spirit is still wide awake.
Analysis found that more than 64,000 Palestinians may have been killed by traumatic injury in the first nine months of the war.
Robotic vehicles from Firefly Aerospace of Texas and Ispace of Japan launched from the same SpaceX rocket early Wednesday and will soon part ways. Both are aiming for the lunar surface.
Regulators filed a lawsuit in federal court stemming from Mr. Musk’s $44 billion purchase of the social media company now called X.